Floatz logo

Pomalidomide

Bioequivalence

Jiangsu Simcere Pharmaceutical Co., Ltd.Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Bioequivalence cohort.

Asset / SponsorPhaseRating
bh009
Zhuhai Beihai Biotech Co., Ltd
Phase 3BB
Docetaxel
Zhuhai Beihai Biotech Co., Ltd
Phase 3B
AMISULPRIDE
The Affiliated Hospital of Qingdao University
Phase 1CC
Inno-206
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
N/AD

Same molecule, other indications

Pomalidomide is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
63 / 100
View asset →
AmyloidosisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →